National Psoriasis Foundation
Advertisement

New oral drug for psoriasis inches closer to the market

Melissa Leavitt

People with psoriasis are one step closer to another oral treatment option.

Tofacitinib, which is taken as a pill, can successfully treat moderate to severe plaque psoriasis, according to results from two Phase III trials released this week.

The trials, which tested the safety and efficacy of two separate doses of the drug, showed that tofacitinib was more effective than a placebo at reducing psoriasis severity. After 16 weeks, a significant number of patients in the trials achieved a 75 percent reduction in severity, and an assessment of "clear" or "almost clear" skin. Each trial enrolled more than 900 patients. No new safety concerns were raised by the trials.

Pfizer, the manufacturer of tofacitinib, plans to submit these results, along with the results of three other trials, by early 2015 as part of a drug approval application to the U.S. Food and Drug Administration.

Tofacitinib targets Janus kinase, an enzyme linked to psoriasis inflammation. It is currently available in the U.S. under the brand name of Xeljanz for the treatment of rheumatoid arthritis.

Learn more about psoriatic disease treatments in the drug pipeline.

Advertisement


Did you enjoy this article? Want to read more?

Check out more from Psoriasis Advance »

Advertisement

 

Copyright © 1996-2013 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation. National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

National Psoriasis Foundation | 6600 SW 92nd Ave., Suite 300, Portland, OR 97223
getinfo@psoraisis.org | www.psoriasis.org

National Psoriasis FoundationNational Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.

CONTACT US

getinfo@psoriasis.org
800-723-9166

National Office:
6600 SW 92nd Ave., Ste. 300
Portland, OR 97223


Washington D.C. Office:
1800 Diagonal Rd., Ste. 360
Alexandria, VA 22314


Site Feedback »

Copyright © 1996-2014 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation.

The National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

The National Psoriasis Foundation does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

Member of Community Health Charities National Health CouncilFour Star Charity Navigator Rating